IPM vs NVDA

The deterministic health profile is weak, highlighted by a Piotroski F-Score of 2/9 and a completely bearish technical trend (0/100). While the company exhibits astronomical year-over-year revenue growth (2091.60%) and maintains a very low debt-to-equity ratio (0.06), these are overshadowed by a chronic inability to meet earnings expectations, with 0 beats in the last four quarters and a massive average surprise of -439.98%. The disconnect between the single analyst's target price of $6.50 and the actual financial performance suggests a high-risk speculative profile rather than a value investment.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.